Top 18 Pharmaceutical Manufacturing Investors in the US
Top 18 Pharmaceutical Manufacturing Investors in the US
The pharmaceutical manufacturing industry in the United States is a critical sector focused on developing and producing medications. Companies range from large global corporations to innovative startups, each contributing to the production of vital drugs, vaccines, and medical treatments. As technology evolves, the industry is increasingly integrating digital solutions and advanced manufacturing techniques to improve efficiency and compliance. In recent years, a shift towards personalized medicine and biologics has emerged, aiming to tailor treatments to individual patient needs. This focus on cutting-edge innovations positions the industry for exciting developments in health care outcomes and patient solutions.
The investors listed here represent a mix of venture capital and private equity firms, predominantly located in major hubs like New York and California. Founded between 1976 and 2017, these investors range in size from small teams to significant firms with thousands of employees. Their deal counts in 2024 vary widely; prominent investors made considerable contributions to the pharmaceutical sector, shaping its future through funding and strategic support. Each investor reflects a commitment to the healthcare ecosystem, helping foster breakthroughs in pharmaceutical manufacturing.
Top 18 Pharmaceutical Manufacturing Investors in the US
1. OrbiMed
- Website: orbimed.com
- Type: Venture Capital
- Headquarters: New York, New York, United States (USA)
- Founded year: 1989
- Headcount: 51-200
- Number of deals in 2024: 52
- LinkedIn: orbimed-advisors
OrbiMed is an investment firm based in New York, specializing in healthcare investments since its founding in 1989. With approximately $17 billion in assets under management, OrbiMed focuses on companies engaged in biopharmaceuticals, medical devices, and healthcare services. The firm has been actively involved in various funding rounds for pharmaceutical companies, including significant investments in Acceleron Pharma, which raised multiple rounds of funding totaling over $100 million, and Sierra Oncology, which secured $59.5 million in a Series D round. Additionally, OrbiMed's investment in Eddingpharm (Cayman), a company focused on obtaining drug licenses and co-developing new prescription drugs in China, further highlights their commitment to the pharmaceutical manufacturing sector. OrbiMed's diverse portfolio and strategic investments position it as a key player in driving innovation within the healthcare industry.
2. Perceptive Advisors
- Website: perceptivelife.com
- Type: Venture Capital
- Headquarters: New York, New York, United States (USA)
- Founded year: 1999
- Headcount: 11-50
- Number of deals in 2024: 45
- LinkedIn: perceptive-advisors-llc
Perceptive Advisors is a New York-based venture capital firm founded in 1999, specializing in the life sciences sector. The firm provides capital solutions and investment management services to both private and public healthcare companies, with a strong focus on biotechnology, pharmaceuticals, and medical devices. Their expertise in the healthcare industry enables them to support innovation and growth through strategic investments. Notable transactions include a $226 million Series C funding for Affinivax, which is involved in vaccine development, and participation in a $130 million equity financing round for Prometheus Biosciences, a biotechnology company focused on developing therapies for autoimmune diseases. Additionally, they have invested in ReViral, which raised funds to support clinical development of antiviral therapies. These transactions highlight Perceptive Advisors' commitment to advancing pharmaceutical manufacturing and biotechnology.
3. New Enterprise Associates (NEA)
- Website: nea.com
- Type: Venture Capital
- Headquarters: Menlo Park, California, United States (USA)
- Founded year: 1977
- Headcount: 51-200
- Number of deals in 2024: 57
- LinkedIn: new-enterprise-associates
New Enterprise Associates (NEA) is a prominent venture capital firm founded in 1977, based in Menlo Park, California. With a focus on investment management and advisory services, NEA specializes in supporting startups, particularly in the technology and healthcare sectors. The firm emphasizes long-term relationships with entrepreneurs, providing not only funding but also strategic guidance to help them navigate the complexities of building successful businesses. NEA has been involved in several notable transactions in the pharmaceutical manufacturing context, including investments in Amplyx Pharmaceuticals, where they participated in multiple funding rounds (Series B and Series C) totaling over $90 million. Additionally, NEA was involved in the Post-IPO equity financing of TESARO, which raised approximately $155 million. These transactions highlight NEA's active role in the pharmaceutical sector, reinforcing their relevance as an investor in pharmaceutical manufacturing.
4. Sosv
- Website: sosv.com
- Type: Venture Capital
- Headquarters: United States (USA)
- Founded year: 1995
- Headcount: 51-200
- Number of deals in 2024: 170
- LinkedIn: sosv
SOSV is a venture capital firm founded in 1995, specializing in funding and supporting deep tech startups through its development programs. With a focus on health and climate technology, SOSV provides venture capital investment and resources to help startups grow and succeed. Notably, they have invested in Pannex Therapeutics Inc., a company engaged in therapeutic development, through multiple funding rounds including seed rounds and a convertible note from 2021 to 2023. This demonstrates their active role in the pharmaceutical sector, particularly in supporting innovative health solutions. Additionally, they have invested in Cell Reserves, further showcasing their interest in health-related startups. SOSV operates globally, connecting innovative companies with investors, and has made 170 investments in 2024 alone, indicating a robust investment strategy.
5. Pfizer
- Website: pfizer.com
- Type: Corporate
- Headquarters: New York, New York, United States (USA)
- Founded year: 1849
- Headcount: 10001+
- Number of deals in 2024: 10
- LinkedIn: pfizer
Pfizer Inc. is a prominent pharmaceutical and biotechnology company founded in 1849, headquartered in New York, New York, USA. With over 10,000 employees, Pfizer develops and produces a diverse array of medicines and vaccines aimed at improving patient health outcomes. The company operates globally, addressing urgent health needs across various therapeutic areas. Notable transactions include the acquisition of Seagen for $31 billion, which aims to bolster Pfizer's oncology portfolio, and the acquisition of Arena Pharmaceuticals for $6.7 billion, enhancing its capabilities in immunology. Additionally, Pfizer's acquisition of Amplyx Pharmaceuticals, focused on therapies for invasive fungal infections, further illustrates its active role in pharmaceutical development. These strategic investments highlight Pfizer's ongoing commitment to advancing pharmaceutical manufacturing and innovation.
6. Vivo Capital
- Website: vivocapital.com
- Type: Venture Capital
- Headquarters: Palo Alto, California, United States (USA)
- Founded year: 1996
- Headcount: 51-200
- Number of deals in 2024: 19
- LinkedIn: vivo-capital
Vivo Capital is an investment firm founded in 1996, based in Palo Alto, California, specializing in healthcare. The firm provides venture capital, private equity, and public equity investments to healthcare companies, facilitating innovation and growth in the sector. Vivo Capital has been involved in various significant transactions within the pharmaceutical manufacturing context, such as a private placement with Sinovac Biotech, which raised $86.73 million to enhance research capabilities and build production facilities for vaccine projects. They also participated in funding rounds for companies like Sagent Pharmaceuticals, which focuses on product launches and development activities in the pharmaceutical space. Their portfolio reflects a strong commitment to advancing healthcare technologies and products, particularly in the pharmaceutical manufacturing industry.
7. Y Combinator
- Website: ycombinator.com
- Type: Venture Capital
- Headquarters: San Francisco, California, United States (USA)
- Founded year: 2005
- Headcount: 51-200
- Number of deals in 2024: 802
- LinkedIn: y-combinator
Y Combinator is a prominent startup accelerator and venture capital firm based in San Francisco, California, founded in 2005. It provides funding and mentorship to early-stage technology companies, having successfully launched over 4,000 startups. In addition to its broad focus on technology, Y Combinator has made significant investments in the pharmaceutical manufacturing sector. For instance, they participated in the funding rounds for Sensible Biotechnologies, which is developing a cell-based platform for cost-efficient mRNA manufacturing, and Shasqi, which raised $10 million for GMP manufacturing to support a Phase 1 human trial. These investments highlight Y Combinator's commitment to fostering innovation in the life sciences and pharmaceutical manufacturing industries, making it a key player in this space.
8. Frazier Healthcare Partners
- Website: frazierhealthcare.com
- Type: Venture Capital
- Headquarters: Seattle, Washington, United States (USA)
- Founded year: 1991
- Headcount: 51-200
- Number of deals in 2024: 27
- LinkedIn: frazier-healthcare-partners
Frazier Healthcare Partners is a venture capital firm based in Seattle, Washington, specializing in healthcare and life sciences investments. Founded in 1991, the firm focuses on growth buyout investments in profitable healthcare businesses and innovative biopharmaceuticals. They have been involved in several notable transactions in the pharmaceutical sector, including a $59.5 million Series D investment in Sierra Oncology in 2014, and multiple funding rounds for Portola Pharmaceuticals, which raised $46 million in Series B, $70 million in Series C, and $60.1 million in another Series C round. These investments highlight Frazier's commitment to advancing pharmaceutical manufacturing and supporting companies that are developing critical healthcare solutions.
9. ARCH Venture Partners
- Website: archventure.com
- Type: Venture Capital
- Headquarters: Chicago, Illinois, United States (USA)
- Founded year: 1986
- Headcount: 11-50
- Number of deals in 2024: 32
- LinkedIn: arch-venture-partners
ARCH Venture Partners is a venture capital firm based in Chicago, Illinois, founded in 1986. The firm specializes in biotechnology investments, providing funding and strategic support to innovative companies in the life sciences sector. They primarily focus on early-stage biotech firms that are developing groundbreaking medical solutions. Notably, ARCH has been involved in significant transactions such as the $800 million financing for Resilience, a company dedicated to transforming pharmaceutical manufacturing in response to COVID-19. This investment highlights their commitment to advancing manufacturing technologies in the pharmaceutical industry. Additionally, ARCH has invested in companies like Vir Biotechnology and VBI Vaccines, which are also engaged in the development of medical solutions, further emphasizing their relevance in the pharmaceutical manufacturing context.
10. Invus
- Website: invus.com
- Type: Venture Capital
- Headquarters: New York, New York, United States (USA)
- Founded year: 1985
- Headcount: 51-200
- Number of deals in 2024: 35
- LinkedIn: invus
Invus is a venture capital investment firm based in New York, specializing in equity investments and investment management since its founding in 1985. The firm partners with owner-managers across various industries to enhance business performance and create sustainable value, with a focus on long-term growth. Invus operates globally, leveraging its expertise to navigate complex investment landscapes. Notably, Invus has made significant investments in the pharmaceutical sector, including a prominent role in the $450 million Series E-K funding round for Moderna Therapeutics, a leading biotechnology company. They also co-led a $93 million Series B financing for Oyster Point Pharmaceuticals, which is dedicated to developing treatments for Dry Eye Disease. Furthermore, Invus has consistently invested in Lexicon Pharmaceuticals, participating in multiple post-IPO equity rounds, including a recent $250 million investment in March 2024. These transactions underscore Invus's active engagement and commitment to the pharmaceutical manufacturing industry.
11. Janus Henderson Investors
- Website: janushenderson.com
- Type: Private Equity
- Headquarters: Denver, Colorado, United States (USA)
- Founded year: 2017
- Headcount: 1001-5000
- Number of deals in 2024: 39
- LinkedIn: janus-henderson-emea
Janus Henderson Investors is an asset management firm based in Denver, Colorado, with a global reach from its headquarters in London. Founded in 2017, the firm provides a range of investment products, including ETFs, mutual funds, and managed accounts, aimed at individual investors, financial professionals, and institutional clients. In 2024, Janus Henderson has made 39 investments, showcasing their active role in the investment landscape. Among their notable transactions in the pharmaceutical sector, they participated in the Series D financing round for FORMA Therapeutics, which raised $100 million to advance clinical development for sickle cell disease and other treatments. Additionally, they were involved in the Series A funding for BioNTech, which raised $270 million, highlighting their engagement in innovative pharmaceutical solutions. Their investments in companies like VelosBio and Everest Medicines further demonstrate their commitment to supporting the development of pharmaceutical products and technologies.
12. Rock Springs Capital
- Website: rockspringscapital.com
- Type: Venture Capital
- Headquarters: Baltimore, Maryland, United States (USA)
- Founded year: 2013
- Headcount: 51-200
- Number of deals in 2024: 16
- LinkedIn: knectit
Rock Springs Capital is a venture capital investment firm based in Baltimore, Maryland, founded in 2013. The firm specializes in investment management and related financial services, catering to clients seeking asset management solutions. Rock Springs Capital has been actively involved in the pharmaceutical sector, with notable transactions including an $80 million investment in Bristol-Myers Squibb in 2017, a $30 million investment in Zai Lab in the same year, and a significant $226 million investment in Affinivax in 2021. More recently, they participated in a post-IPO equity round for Aclaris Therapeutics, raising $80 million in November 2024, following an earlier investment of $40 million in 2015. These transactions highlight Rock Springs Capital's commitment to supporting innovative companies in the pharmaceutical manufacturing space.
13. Redmile Group
- Website: redmilegroup.com
- Type: Venture Capital
- Headquarters: San Francisco, California, United States (USA)
- Founded year: 2007
- Headcount: 11-50
- Number of deals in 2024: 15
- LinkedIn: redmile-group
Redmile Group is an investment management firm based in San Francisco, California, founded in 2007. The firm specializes in providing asset management and investment strategies to high-net-worth individuals and institutional investors. With a focus on the financial services sector, Redmile Group has made notable investments in the pharmaceutical industry, including significant transactions such as a $50 million investment in Blueprint Medicines in 2014, a $70 million investment in CytomX Therapeutics in 2015, and a $52 million investment in Aurinia Pharmaceuticals in 2014. These investments highlight their commitment to supporting innovative companies in the pharmaceutical manufacturing sector, particularly those advancing drug development and therapeutic solutions.
14. Samsara BioCapital
- Website: samsaracap.com
- Type: Venture Capital
- Headquarters: Palo Alto, California, United States (USA)
- Founded year: 2016
- Headcount: 11-50
- Number of deals in 2024: 27
- LinkedIn: samsara-biocapital
Samsara BioCapital is a biotechnology investment firm based in Palo Alto, California, founded in 2016. The firm specializes in investing in innovative therapies and providing essential support to entrepreneurs in the medical field. With a focus on the biotechnology and healthcare sectors, Samsara BioCapital has been involved in numerous significant transactions. For instance, they led a Series E financing round for Sutro Biopharma, raising $85.4 million to support the development of their therapeutic pipeline. Additionally, they participated in a $100 million Series D financing for Forma Therapeutics, which aims to advance clinical development for sickle cell disease and other treatments. In 2024, they co-led a Series C financing round for Alumis, raising $259 million to support the launch of a phase 3 psoriasis trial. These transactions highlight their commitment to advancing pharmaceutical manufacturing and innovative therapies.
15. Polaris Partners
- Website: polarispartners.com
- Type: Venture Capital
- Headquarters: Boston, Massachusetts, United States (USA)
- Founded year: 1996
- Headcount: 11-50
- Number of deals in 2024: 19
- LinkedIn: polaris-partners
Polaris Partners is a venture capital firm founded in 1996 and based in Boston, Massachusetts. The firm specializes in healthcare and biotechnology investments, partnering with entrepreneurs to provide funding and strategic guidance to help them innovate and grow their businesses. Polaris has a diverse portfolio that includes companies focused on transformative healthcare solutions. Notably, they have made significant investments in pharmaceutical companies such as Acceleron Pharma, which raised multiple rounds of funding totaling over $100 million, and Ironwood Pharmaceuticals, which secured $25 million in a venture round. Additionally, they invested in TARIS Biomedical, further emphasizing their commitment to the pharmaceutical sector. Polaris operates primarily in the investment management space, supporting early-stage companies in bringing their products to market.
16. EcoR1 Capital, LLC
- Website: ecor1cap.com
- Type: Venture Capital
- Headquarters: San Francisco, California, United States (USA)
- Founded year: 2012
- Headcount: 11-50
- Number of deals in 2024: 14
- LinkedIn: ecor1-capital-llc
EcoR1 Capital, LLC is a San Francisco-based venture capital firm founded in 2012, specializing in biotech investments. The firm partners with entrepreneurs to develop innovative therapeutics, leveraging its expertise in both science and strategy to support the development of new medicines. EcoR1 Capital has been involved in several notable transactions in the pharmaceutical manufacturing context, including a $120 million Series B financing for Nabriva Therapeutics, which is advancing its lead product into clinical trials for bacterial pneumonia. They also participated in a financing round for Collegium Pharmaceutical, which focuses on the commercial development of abuse-deterrent medications. Other investments include significant funding for Affinivax and Cerevel Therapeutics, both of which are engaged in developing new therapeutic solutions. Overall, EcoR1 Capital's focus on biotech and their involvement in key pharmaceutical projects position them as a relevant investor in the pharmaceutical manufacturing industry.
17. Casdin Capital, LLC
- Website: casdincapital.com
- Type: Venture Capital
- Headquarters: New York, New York, United States (USA)
- Founded year: 2012
- Headcount: 11-50
- Number of deals in 2024: 9
- LinkedIn: casdin-capital-llc
Casdin Capital, LLC is a New York-based venture capital firm founded in 2012, specializing in the life sciences sector. The firm focuses on investing in healthcare, biotechnology, synthetic biology, and technology, providing funding and strategic partnerships to innovative companies. Notable transactions include investments in Blueprint Medicines, which raised significant funding to advance its pipeline of genomically defined product candidates, and CytomX Therapeutics, which secured financing to support its Probody therapeutics. Additionally, Casdin Capital participated in funding rounds for Gritstone bio and Voyager Therapeutics, both of which are engaged in developing advanced therapeutics. Their portfolio reflects a commitment to supporting companies that are at the forefront of pharmaceutical innovation and development.
18. Silicon Valley Bank
- Website: svb.com
- Type: Venture Capital
- Headquarters: Santa Clara, California, United States (USA)
- Founded year: 1983
- Headcount: 5001-10000
- Number of deals in 2024: 31
- LinkedIn: silicon-valley-bank
Silicon Valley Bank is a commercial bank founded in 1983, located in Santa Clara, California, that specializes in providing financial services to the innovation economy, particularly tech startups and venture capital firms. They offer a range of products including business banking, global payments, and asset management, helping clients navigate financial challenges and support their growth. In the pharmaceutical manufacturing context, SVB has been involved in several significant transactions, including a $5 million debt financing for CymaBay Therapeutics in 2013, a $16.9 million debt financing for Pharming Group in 2015, and a $35 million post-IPO debt for Reata Pharmaceuticals in 2017. Additionally, they provided an $11 million term loan facility to Aclaris Therapeutics in 2020. These transactions highlight SVB's active role in supporting pharmaceutical companies, making them a relevant investor in this industry.
Pharmaceutical Manufacturing Insights: Key Investors in the US
| Investor | Headquarter | Size | Founded | Deals 2024 |
|---|---|---|---|---|
| OrbiMed | New York, New York, United States (USA) | 51-200 | 1989 | 52 |
| Perceptive Advisors | New York, New York, United States (USA) | 11-50 | 1999 | 45 |
| New Enterprise Associates (NEA) | Menlo Park, California, United States (USA) | 51-200 | 1977 | 57 |
| Sosv | United States (USA) | 51-200 | 1995 | 170 |
| Pfizer | New York, New York, United States (USA) | 10001+ | 1849 | 10 |
| Vivo Capital | Palo Alto, California, United States (USA) | 51-200 | 1996 | 19 |
| Y Combinator | San Francisco, California, United States (USA) | 51-200 | 2005 | 802 |
| Frazier Healthcare Partners | Seattle, Washington, United States (USA) | 51-200 | 1991 | 27 |
| ARCH Venture Partners | Chicago, Illinois, United States (USA) | 11-50 | 1986 | 32 |
| Invus | New York, New York, United States (USA) | 51-200 | 1985 | 35 |
| Janus Henderson Investors | Denver, Colorado, United States (USA) | 1001-5000 | 2017 | 39 |
| Rock Springs Capital | Baltimore, Maryland, United States (USA) | 51-200 | 2013 | 16 |
| Redmile Group | San Francisco, California, United States (USA) | 11-50 | 2007 | 15 |
| Samsara BioCapital | Palo Alto, California, United States (USA) | 11-50 | 2016 | 27 |
| Polaris Partners | Boston, Massachusetts, United States (USA) | 11-50 | 1996 | 19 |
| EcoR1 Capital, LLC | San Francisco, California, United States (USA) | 11-50 | 2012 | 14 |
| Casdin Capital, LLC | New York, New York, United States (USA) | 11-50 | 2012 | 9 |
| Silicon Valley Bank | Santa Clara, California, United States (USA) | 5001-10000 | 1983 | 31 |
Want to find more investors focusing on the pharmaceutical manufacturing industry?
If you want to find more investors that are active in the pharmaceutical manufacturingindustry, you can do that with Inven. We built this list and analysis throughInven's Investor Search, and there are a lot more private equity, venturecapital, and corporate investors like these globally.With Inven, you'll also get to know:
- Deal History: Number of deals and their sizes.
- Portfolio: Companies they've invested in.
- Contact data: Key dealmakers, including their emails and phonenumbers.
- ...and much more!
.jpg)
Trusted by 700+ companies
